India's Proposed Tweak Of New Drug Rules: Bridge To Data Exclusivity?
Executive Summary
A key Indian advisory panel is expected to consider a crucial tweak to certain regulations pertaining to the approval of “new drugs”, which domestic firms allege could facilitate a different form of data exclusivity and also limit competition.